HEMGENIX Patent Extension Period Set by FDA Regulators
Published Date: 7/14/2025
Notice
Summary
The FDA has officially set the review period for HEMGENIX, a special medicine made from human biological material. This means the company can ask for extra time on their patent to protect their invention. If approved, this extension helps the makers keep their exclusive rights longer, which can impact when generic versions hit the market and affect money flow in the drug world.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA OKs Patent Extension Filing
The FDA has determined the regulatory review period for HEMGENIX, a medicine made from human biological material. Because of that determination, the company can submit an application to the U.S. Patent and Trademark Office (USPTO) to ask for extra time on a patent that claims HEMGENIX.
Possible Delay of Generic Competition
If the USPTO approves a patent extension for HEMGENIX, the maker could keep exclusive rights longer. You may pay higher prices or wait longer for lower-cost generic versions because this extension can affect when generics enter the market and the flow of money in the drug market.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-13047, Agency Information Collection Activities; Proposed Collection; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA wants your thoughts on continuing their study about how well the Real Cost Campaign helps people make healthier choices. This study affects teens and young adults by tracking their habits over time. They’re asking for comments within 60 days—no new costs, just a chance to share your opinion!
Next: 2025-13049, Agency Information Collection Activities; Proposed Collection; Comment Request; Emergency Use Authorization of Medical Products
The FDA wants your thoughts on how they collect info about emergency use of medical products, like vaccines or treatments during health crises. This helps make sure the process is smooth and not too much paperwork for companies and the public. You’ve got 60 days to share your ideas, and this could affect how quickly lifesaving products get approved without extra costs or delays.